Opendata, web and dolomites

TITLY SIGNED

Inhibition of the T-cell receptor signalling pathway for treatment of T-cell lymphoma

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TITLY project word cloud

Explore the words cloud of the TITLY project. It provides you a very rough idea of what is the project "TITLY" about.

vitro    lab    inhibitors    tyrosine    screen    group    rely    compounds    pr    potent    approval    bruton    kinase    signalling    medical    small    lymphocyte    translation    bethesda    place    shrnas    de    national    lyon    louis    11th    btk    researcher    perform    lymphomas    lines    models    works    share    dismal    vivo    rnas    global    function    transformation    non    worldwide    form    first    hairpin    scientifique    revolutionizing    cancer    similarly    staudt    agencies    xenograft    centre    regulatory    mature    salles    gilles    discovery    exceeding    france    lymphoid    united    pharmacological    mainly    came    team    granted    receptor    indolent    15    fellowship    potency    tcr    outgoing    recherche    science    adaptor    cell    rapid    usa    lymphoma    prognosis    la    10th    ie    proliferation    barely    led    technic    therapeutic    dr    inhibitor    bcr    malignancies    functional    basic    treatment    ptcl    fruitfully    named    nhl    hodgkin    previously    return    accelerated    survival    provides    peripheral    branch   

Project "TITLY" data sheet

The following table provides information about the project.

Coordinator
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS 

Organization address
address: RUE MICHEL ANGE 3
city: PARIS
postcode: 75794
website: www.cnrs.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.crcl.fr/638-Salles-genestier.crcl.aspx
 Total cost 178˙603 €
 EC max contribution 178˙603 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-GF
 Starting year 2015
 Duration (year-month-day) from 2015-11-01   to  2017-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) coordinator 178˙603.00
2    United States Department of Health and Human Services US (Washington D.C.) partner 0.00

Map

 Project objective

Non-Hodgkin lymphoma (NHL) is a form of cancer emerging from the transformation of a mature B- or T-cell lymphocyte. NHL is the 11th most common cancer in Europe, and the 10th most common cancer worldwide. Functional evidence of the key role of B-cell receptor (BCR) signalling in B-cell malignancies came mainly from works conducted in Dr Louis Staudt’s lab (National Cancer Institute, Lymphoid Malignancies Branch, Bethesda, USA) where the outgoing phase of the global fellowship would take place. Rapid translation of basic science discovery on the BCR signalling led to the development of a specific inhibitor of a key BCR pathway adaptor named Bruton’s tyrosine kinase (BTK), which was granted for accelerated approval both in United States and Europe by regulatory medical agencies. While the potency of BCR pathway inhibitors is currently revolutionizing the management of B-cell malignancies, peripheral (ie mature) T-cell lymphomas (PTCL) still share a dismal prognosis with a 10-year overall survival barely exceeding 15%. Previous work of the experienced researcher provides strong evidence that PTCL similarly rely on T-cell receptor (TCR) signalling pathway for survival. Targeting this pathway could then lead to discovery of potent therapeutic compounds for PTCL treatment. During the 2 years of the global fellowship, the researcher would first perform a TCR pathway small hairpin RNAs (shRNAs) loss-of-function screen in PTCL cell lines in the group of Dr Louis Staudt where the technic is already available and has been fruitfully applied to B-cell malignancies. Second, the researcher would identify potential pharmacological inhibitors of the previously identified targets both in vitro and in vivo in PTCL cell lines xenograft models. This second phase of the project would take place both among the outgoing team and the return group of Pr Gilles Salles (Centre National de la Recherche Scientifique, Indolent-B-cell Proliferation Branch, Lyon, France).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TITLY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TITLY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MingleIFT (2020)

Multi-color and single-molecule fluorescence imaging of intraflagellar transport in the phasmid chemosensory cilia of C. Elegans

Read More  

NeoPur (2019)

New treatments and novel diagnostic tests for neonatal seizures based on purinergic signaling.

Read More  

MIGPSC (2018)

Shaping the European Migration Policy: the role of the security industry

Read More